This program is intended for primary care professionals, including physicians, physician assistants, and other healthcare professionals who manage patients with IBD.
Upon completion of this activity, participants should be able to:
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Anita Afzali, MD, MPH, MHCM, FACG, AGAF
Professor of Clinical Medicine
Division of Digestive Diseases
Executive Vice Chair
Department of Internal Medicine
Associate Chief Medical Officer
University of Cincinnati, UC Health System
The Scrubs & Heels Foundation
Anita Afzali, MD, MPH, MHCM, FACG, AGAF: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Eli Lilly, IBD Horizons, Janssen, Pfizer, Takeda.
David Hudesman, MD, FACG, AGAF
Associate Professor of Medicine
NYU School of Medicine
Inflammatory Bowel Disease Center at NYU Langone
NYU Langone Health
New York, New York
David Hudesman, MD, FACG, AGAF, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Janssen, Pfizer, Takeda, and UCB and funds for research support from Janssen and Pfizer.
Millie D. Long, MD, MPH, FACG, AGAF
Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Millie D. Long, MD, MPH, FACG, AGAF, has disclosed that she has received consultant/advisor fees from AbbVie, Bristol-Myers Squibb, Calibr, Lilly, Genentech, Janssen, Pfizer, Prometheus, Roche, Takeda, Theravance, and Target Pharmasolutions.
Ruth Cohen Cooper, CHCP, has no relevant financial relationships to disclose.
Kiran Mir-Hudgeons, PhD
Kiran D. Mir-Hudgeons, PhD, has no relevant financial relationships to disclose.
Laurie Rosales, MS, APRN-CNP
Laurie Rosales, MS, APRN-CNP, has no relevant financial relationships to disclose.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until June 23, 2023. PAs should only claim commensurate with the extent of their participation.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 24, 2022, through June 23, 2023:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
This program has been made available online.
The goal of this activity is to improve learners’ knowledge and competence regarding recent advances in therapy, individualized IBD management, and health inequities affecting patients with IBD.